Lakefront Biotherapeutics (LKFT) Current Assets (2013 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Current Assets for 13 consecutive years, with $3.6 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Current Assets fell 1.89% year-over-year to $3.6 billion; the TTM figure through Mar 2026 stood at $3.6 billion (down 1.89% YoY), while the FY2025 annual figure was $3.6 billion, changed 0.45% from the prior year.
• Current Assets was little changed at $3.6 billion in Q1 2026 per LKFT's latest filing, from $3.6 billion in the prior quarter.
• Across five years, Current Assets topped out at $5.3 billion in Q1 2022 and bottomed at $3.6 billion in Q4 2024.
• Historically, Current Assets has averaged $4.0 billion across 5 years, with a median of $3.9 billion in 2024.
• Annual changes were most pronounced in 2022 — Current Assets decreased 22.28% — and 2025, when it climbed 0.45%.
• Lakefront Biotherapeutics' Current Assets stood at $4.3 billion in 2022, then retreated by 3.88% to $4.2 billion in 2023, then retreated by 14.11% to $3.6 billion in 2024, then gained by 0.45% to $3.6 billion in 2025, then retreated by 0.04% to $3.6 billion in 2026.
• Business Quant data shows LKFT's Current Assets at $3.6 billion in Q1 2026, $3.6 billion in Q4 2025, and $3.7 billion in Q3 2025.